InflaRx (IFRXN) Price & Analysis
IFRXN Stock Chart & Stats
- Day’s Range
- MXN 35.00 - MXN 35.00
- 52-Week Range
- MXN 22.00 - MXN 36.00
- Previous Close
- MXN 35.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 4.60B
- Enterprise Value
- MXN 83.29M
- Total Cash (Recent Filing)
- MXN 158.45M
- Total Debt (Recent Filing)
- MXN 832.83K
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Nov 03, 2026
- EPS Estimate
- -1.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces refinancing pressure and preserves financial flexibility relative to a more debt-dependent biotech. Although it does not eliminate funding needs, the limited debt burden should reduce interest-related strain and leave more strategic options as the pipeline advances.
Focused Complement Pipeline
A focused therapeutic strategy around complement-driven inflammation gives InflaRx a clear scientific identity and concentrates resources on related disease opportunities. The lead antibody and additional complement programs provide a coherent platform for potential clinical development and partnering.
Ongoing R&D Investment
Continued research and development spending indicates that InflaRx is maintaining efforts to advance its therapeutic pipeline rather than abandoning development activity. For a clinical-stage company, sustained R&D is necessary to generate clinical, regulatory, and eventual partnering milestones.
Bears Say
Persistent Cash Burn
Persistent operating and free-cash-flow deficits show that the business is not yet self-funding. Continued cash consumption can require additional capital raises, increasing financing dependence and potentially limiting the company’s ability to sustain development without external support.
Deep Operating Losses
The absence of a meaningful revenue base and continuing large operating losses indicate that commercial economics have not yet been established. Until a program produces recurring revenue, InflaRx remains dependent on clinical progress and future financing rather than operating earnings.
Equity Dilution Risk
Material changes in shareholder equity, combined with ongoing losses and cash needs, increase the risk that future operations will require equity financing. Additional issuance could dilute existing holders and may constrain capital allocation while the pipeline remains uncommercialized.
InflaRx News
IFRXN FAQ
What was InflaRx’s price range in the past 12 months?
What is InflaRx’s market cap?
When is InflaRx’s upcoming earnings report date?
How were InflaRx’s earnings last quarter?
Is InflaRx overvalued?
Does InflaRx pay dividends?
What is InflaRx’s EPS estimate?
How many shares outstanding does InflaRx have?
What happened to InflaRx’s price movement after its last earnings report?
Which hedge fund is a major shareholder of InflaRx?
What is the TipRanks Smart Score and how is it calculated?
InflaRx Stock Smart Score
Company Description
InflaRx
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Niels C. Riedemann
- Employees
- 65
- Website
- www.inflarx.de
- Address
- Winzerlaer Str. 2, Jena, TH, 07745, DE
InflaRx (IFRXN) Earnings & Revenues
IFRXN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 0 |
| Technical Analysis | 4 | 0 | 0 |
| Moving Averages | 8 | 4 | 0 |